INTRODUCTION
urothelial cancer, cancer, UC, MIBC, Bladder cancer
BLADDER CANCER, CANCER
Bladder cancer is the tenth most commonly diagnosed cancer worldwide, with a higher prevalence in males than females, and Southern Europe, Western Europe, and Northern America being the regions with the highest incidence rates.Immune checkpoint inhibitors (ICIs) monotherapy has been approved by the US Food and Drug Administration for treating advanced or metastatic urothelial cancer (UC) in patients who have failed chemotherapy or as first‐line therapy for platinum‐ineligible patients.Several trials have demonstrated the anti‐tumor activity of different ICI‐chemotherapy combinations as perioperative treatment for resectable MIBC patients.